MRNA: Morgan Stanley keeps Equalweight, raises PT to $89
Morgan Stanley maintains an Equalweight rating on MRNA and raises its price target to $89, according to TradeXchange Newsdesk.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.